Acute Pyelonephritis Market By Treatment and Service Type (Standard Antibiotic Therapies, Resistant-Infection Therapies, Rapid Diagnostics and Antimicrobial Susceptibility Testing, Infusion and Acute-Care Delivery Services), By Care Setting (Inpatient Care, Outpatient Care, Hospital-at-Home), By End User (Hospitals and Emergency Departments, Specialty Clinics, Diagnostic Laboratories, Home Healthcare Providers), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Acute Pyelonephritis Market: Evolving Treatment Complexity, Resistance-Driven Demand, and Shifting Commercial Value Across Care Settings

The Global Acute Pyelonephritis Market was valued at an estimated USD 1.86 billion in 2025 and is projected to reach USD 2.71 billion by 2032, expanding at a CAGR of 5.5% during 2026–2032. Segment shares, revenues, and growth rates are modeled estimates aligned with these total market values.

 

Acute pyelonephritis is a bacterial kidney infection, usually caused by ascending E. coli, with urinary obstruction, stones or reflux increasing the risk. Treatment is selected according to disease severity, urine-culture susceptibility and local resistance patterns; urinary obstruction requires urgent source control. Oral step-down options include ciprofloxacin or levofloxacin, which inhibit DNA gyrase and topoisomerase IV, and trimethoprim–sulfamethoxazole, which blocks sequential steps in bacterial folate synthesis. Severe infections may require IV ceftriaxone or cefepime, piperacillin–tazobactam, carbapenems such as ertapenem, meropenem or imipenem–cilastatin, or aminoglycosides such as gentamicin, amikacin or plazomicin. β-lactams inhibit PBP-mediated cell-wall synthesis, β-lactamase inhibitors protect partner antibiotics, and aminoglycosides inhibit protein synthesis by binding the 30S ribosomal subunit.

 

Important therapies for resistant Gram-negative infections include meropenem–vaborbactam for KPC-producing bacteria; ceftazidime–avibactam and imipenem–relebactam, which inhibit major serine β-lactamases; cefiderocol, which uses bacterial iron-transport pathways before inhibiting PBPs; cefepime–enmetazobactam, which protects cefepime against ESBLs; and cefepime–zidebactam, which combines PBP3 inhibition by cefepime with PBP2 binding and β-lactamase inhibition by zidebactam. Tebipenem pivoxil is an oral carbapenem prodrug that inhibits PBP-mediated cell-wall synthesis. Cefepime–zidebactam and tebipenem pivoxil received FDA approval in 2026.

 

Investigational agents include cefepime–taniborbactam, targeting serine and metallo-β-lactamases, and NRX-101, in which D-cycloserine inhibits cell-wall precursor enzymes while lurasidone is intended to reduce CNS adverse effects; the registered NRX-101 study currently has an unknown recruitment status.

 

In the U.S., the condition affects an estimated 250,000 people annually, with an incidence of about 15–17 cases per 10,000 females and 3–4 per 10,000 males, and roughly 15%–20% of patients requiring hospitalization. It occurs globally without racial predisposition and is most common in young sexually active women, pregnant individuals, and older adults. This patient distribution supports a large outpatient treatment base alongside a higher-value inpatient segment driven by clinical complexity and longer hospital stays.

 

Emergency-Department Volume Maintains a Large Treatment Base

Recent U.S. emergency-department data highlight the scale of acute pyelonephritis care. Across 205.5 million adult ED visits from 2016 to 2023, there were about 1.04 million cases, representing 0.5% of visits. Around 33.4% of patients were admitted, and this share gradually increased, supporting steady inpatient demand.

Antibiotic use is dominated by cephalosporins. In admitted patients, third-generation cephalosporins accounted for 55.6% of treatments, while discharged patients most commonly received first- and third-generation cephalosporins, along with ciprofloxacin and trimethoprim-sulfamethoxazole. Overall, prescribing trends show rising cephalosporin use and declining fluoroquinolone use, strengthening demand for hospital injectable antibiotics.

Global data show similar patterns. In South Korea, incidence rose from 35.6 to 43.8 cases per 10,000 people between 2010 and 2014, with higher rates in women and older adults. In Spain, about 90% of prescriptions come from cephalosporins, quinolones, and penicillins, reflecting reliance on established antibiotic classes and limiting pricing growth.

Pregnancy is a key high-risk segment, with 1%–2% of pregnant individuals affected. It is a common cause of hospitalization and requires inpatient IV antibiotics and extended treatment because of risks such as sepsis and preterm delivery.

 

Antimicrobial Resistance Drives the Highest-Value Demand

Antimicrobial resistance is a major growth driver in acute pyelonephritis because it reduces the effectiveness of standard oral antibiotics, often leading to treatment failure, IV therapy, and longer hospital stays. The CDC estimates ESBL-producing Enterobacterales caused about 197,400 infections and 9,100 deaths in U.S. hospitals in 2017, including urinary and bloodstream infections.

Resistant-infection therapies and diagnostics made up about 23% of the market in 2025 (USD 0.43 billion) and are expected to rise to 30% (USD 0.81 billion) by 2032, growing at a strong 9.6% CAGR. In contrast, standard treatments remain the largest share at 77% in 2025 (USD 1.43 billion), growing more slowly at 4.1% CAGR.

Resistance is increasingly common in complicated cases, with fluoroquinolone resistance reaching up to 19.9% and ESBL-producing bacteria 12.2% in U.S. data, often requiring broader-spectrum antibiotics.

Treatment is now more guided by culture results and local resistance patterns, with guidelines recommending IV review within 48 hours and switching to oral therapy when possible. This supports more targeted antibiotic use and continued demand for advanced therapies in resistant cases.

Demand for rapid diagnostics is also rising, supporting an 8.3% CAGR for the diagnostic segment. WHO’s 2025 report covered over 23 million confirmed infections across 104 countries in 2023, highlighting the global scale of resistance monitoring.

 

New Approvals Reshape the Resistant-Infection Segment

The U.S. treatment landscape for acute pyelonephritis evolved quickly between 2024 and 2026, with several key FDA approvals targeting resistant infections.

In 2024, the FDA approved EXBLIFEP (cefepime + enmetazobactam) for complicated UTIs including pyelonephritis. In a 1,041-patient trial, it showed a 79.1% response rate versus 58.9% with piperacillin-tazobactam, with higher clinical and microbiological cure rates, supporting its use in hospital-treated resistant infections.

In 2026, Wockhardt’s ZAYNICH (cefepime-zidebactam) was approved for cUTIs. In a Phase III study of 530 patients, it achieved an 89.0% response versus 68.4% for meropenem, with strong microbiological outcomes, positioning it for resistant hospital cases.

Also in 2026, the FDA approved UTEBZI (oral tebipenem pivoxil), the first oral carbapenem for cUTIs including pyelonephritis. In a 1,690-patient trial, it showed similar efficacy to IV imipenem-cilastatin and may help reduce IV use and enable earlier hospital discharge in selected patients.

Overall, these approvals are expanding treatment options for resistant infections while shifting care toward more targeted, cost-efficient use of hospital resources.

 

Reimbursement Rewards Efficient Use of Inpatient Resources

U.S. hospital reimbursement does not assign acute pyelonephritis a separate payment category. Under the CMS FY2025 MS-DRG system, cases fall under DRG 689 (with major complications/comorbidities) or DRG 690 (without), meaning payments depend mainly on illness severity and resource use rather than diagnosis alone.

This structure encourages hospitals to reduce length of stay, avoid treatment failure, and shift stable patients out of inpatient care. As a result, antibiotics that may cost more upfront can still be preferred if they shorten hospitalization or prevent complications. This supports inpatient market growth, projected to rise from USD 1.08 billion in 2025 to USD 1.68 billion by 2032.

CMS has also expanded its Acute Hospital Care at Home program, launched in 2020 and extended through 2030, with updated data released in 2026. This model allows selected patients to receive hospital-level care at home with IV antibiotics, monitoring, and rapid escalation if needed.

A Mayo Clinic study of 165 acute pyelonephritis patients (2020–2025) showed hospital-at-home is being used even in older and more severe cases, with a median age of 67 and over half having major illness severity.

This shift is driving demand for home infusion services, remote monitoring, and nursing support. The acute-care-at-home services market is expected to grow from USD 0.22 billion in 2025 to USD 0.33 billion by 2032 (5.5% CAGR). New oral therapies like UTEBZI may further reduce IV use in selected patients, but adoption will depend on patient eligibility, reimbursement, and safety outcomes.

 

North America Leads Through Hospital Spending and Regulatory Access

North America held about 39.0% of the market in 2025, generating roughly USD 0.73 billion, and is expected to reach USD 1.06 billion by 2032 at a 5.6% CAGR. The U.S. leads due to high hospital use, strong diagnostic capacity, and broad access to new antibiotics.

UTIs drive significant demand, with about 2.7 million U.S. emergency visits and around 400,000 hospitalizations annually, creating an estimated USD 2.8 billion in healthcare costs. These figures reflect the wider UTI and cUTI burden that supports pyelonephritis treatment demand.

Recent FDA approvals such as EXBLIFEP, ZAYNICH, and UTEBZI are strengthening the treatment landscape, but their use is expected to remain focused on resistant or complicated cases under strict hospital formulary control.

CMS’s Hospital Care at Home program, extended through 2030, is also supporting growth in home-based IV-to-oral treatment pathways and remote infection management.

 

Europe Balances Resistant-Infection Demand with Strict Stewardship

Europe accounted for about 28.0% of the market in 2025, generating USD 0.52 billion, and is expected to reach USD 0.72 billion by 2032 at a 4.7% CAGR. Growth is slower than the global average due to strict reimbursement rules, hospital tendering, and strong antimicrobial stewardship policies that limit broad use of premium antibiotics.

According to ECDC, 61.5% of antibiotic use in the EU in 2023 came from WHO “Access” group drugs, still below the 65% 2030 target. Around 90% of antibiotic use occurs in the community setting, highlighting tight outpatient prescribing control.

Resistance trends remain mixed. E. coli bloodstream infections resistant to third-generation cephalosporins fell by 3.6% from 2019 to 2023, but carbapenem-resistant Klebsiella pneumoniae cases rose by nearly 60%, supporting continued demand for advanced hospital antibiotics.

Adoption varies across the region, with higher resistance levels in southern and southeastern Europe driving greater use of advanced therapies, while northern and western countries maintain stricter prescribing controls.

 

Asia-Pacific Records the Fastest Modeled Expansion

Asia-Pacific accounted for an estimated 24.0% market share and USD 0.45 billion in revenue in 2025 and is projected to reach about USD 0.69 billion by 2032, growing at a CAGR of 6.4%, making it the fastest-growing region.

Growth is driven by a large patient base, rising hospital access, and increasing antibiotic resistance. In South Korea, acute pyelonephritis incidence rose from 35.6 to 43.8 cases per 10,000 people between 2010 and 2014, with women more frequently affected.

WHO reports that about one in three bacterial infections in South-East Asia is antibiotic-resistant, compared with one in six globally, highlighting strong demand for effective therapies.

Growth is strongest in developed markets like Japan, South Korea, China, Australia, and India’s major hospital networks, where advanced diagnostics and newer antibiotics are more accessible, while lower-income markets still rely mainly on generic antibiotics.

 

Latin America, the Middle East, and Africa Offer Selective Hospital Demand

Latin America, the Middle East, and Africa collectively represented an estimated 9.0% share and USD 0.17 billion in revenue in 2025. This combined segment is projected to reach approximately USD 0.24 billion by 2032 at a CAGR of 5.3%.

WHO reports high antibiotic resistance in these regions, with about 1 in 3 infections resistant in the Eastern Mediterranean and 1 in 5 in Africa in 2023. In parts of Africa, resistance to key Gram-negative bacteria exceeds 70%, increasing reliance on stronger hospital-based antibiotics.

However, true market size is difficult to measure due to weak surveillance. Although 104 countries reported data to WHO GLASS in 2023, nearly half did not submit data, and many reporting countries still lack reliable testing systems, meaning resistance levels may be underreported.

In the near term, demand will remain concentrated in hospitals and urban healthcare centers. Generic antibiotics will continue to dominate most treatments, while newer or protected therapies will mainly be used for severe or confirmed resistant infections such as sepsis or treatment failure cases.

 

Competitive Advantage Will Depend on Treatment Placement

Generic antibiotics will continue to dominate most uncomplicated and low-risk infections due to their low cost and wide availability, limiting the use of premium drugs in routine cases. New branded antibiotics are mainly reserved for resistant infections, treatment failures, hospital-acquired cases, or patients with limited oral options.

Recent FDA approvals such as EXBLIFEP and ZAYNICH target serious IV-treated resistant infections, while UTEBZI (oral tebipenem) offers an oral carbapenem option that may help reduce IV hospital stays in selected patients. These therapies are used selectively in high-risk cases and are not broadly interchangeable. Hospital formularies typically decide their use based on local resistance patterns, infection severity, and overall treatment cost, with guidelines recommending carbapenems and newer broad-spectrum antibiotics be reserved for confirmed or strongly suspected multidrug-resistant infections.

 

Analyst Perspective: Growth Will Come from Treatment Intensity, Not Routine Prescriptions

The acute pyelonephritis market’s 5.5% CAGR reflects a shift in where value is generated rather than broad prescription growth. Generic antibiotics will continue to dominate most uncomplicated cases, limiting pricing upside. Growth is instead driven by hospital admissions, resistant infections, rapid diagnostics, oral step-down therapies, and hospital-at-home care.

The resistant-infection segment is projected to rise from USD 0.43 billion in 2025 to USD 0.81 billion by 2032 (9.6% CAGR), supported by rising antimicrobial resistance. WHO reports that about 1 in 6 bacterial infections was resistant in 2023, with resistance increasing in over 40% of monitored pathogen–antibiotic pairs between 2018 and 2023.

Diagnostics are also expanding at an 8.3% CAGR as faster testing is essential for selecting effective antibiotics and reducing treatment failure. This supports more targeted use of newer, higher-value therapies.

Recent approvals are reshaping care delivery. UTEBZI, the first oral carbapenem (FDA 2026), may reduce IV therapy duration and support earlier discharge or hospital-at-home use in selected patients. EXBLIFEP (2024) and ZAYNICH (2026) remain important IV options for severe or resistant infections, with use focused on hospitalized patients rather than broad outpatient care.

 

Acute Pyelonephritis Market Report Coverage Table

 

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.86 Billion
Revenue Forecast in 2032	USD 2.71 Billion
Overall Growth Rate	CAGR of 5.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Treatment and Service Type, By Care Setting, By End User, By Geography
By Treatment and Service Type	Standard Antibiotic Therapies, Resistant-Infection Therapies, Rapid Diagnostics and Antimicrobial Susceptibility Testing, Infusion and Acute-Care Delivery Services
By Care Setting	Inpatient Care, Outpatient Care, Hospital-at-Home
By End User	Hospitals and Emergency Departments, Specialty Clinics, Diagnostic Laboratories, Home Healthcare Providers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising antimicrobial resistance, increasing demand for targeted antibiotic therapies, growing hospitalization for complicated infections, expansion of rapid diagnostics and antimicrobial susceptibility testing, adoption of hospital-at-home care models
Customization Option	Available upon request